Literature DB >> 6661735

Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer.

H Y Yap, L Esparza, G R Blumenschein, G N Hortobagyi, G P Bodey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6661735     DOI： 10.1016/0305-7372(83)90023-3

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  4 in total

1.  A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.

Authors:  J M Bennett; P Byrne; A Desai; C White; R DeConti; C Vogel; E Krementz; F Muggia; J Doroshow; D Plotkin
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

2.  Comparative in vitro toxicity of mitoxantrone and adriamycin in human granulocyte-macrophage progenitor cells.

Authors:  H G Mergenthaler; P Brühl; G Ehninger; E Heidemann
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Mitoxantrone as a first-line treatment of advanced breast cancer.

Authors:  K Landys; S Borgstrom; T Andersson; H Noppa
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 4.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.